You just read:

Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer's Disease Patients

News provided by

Longeveron

10 May, 2017, 11:19 ET